Department of Psychiatry, Psychotherapy and Psychosomatic Medicine Incorporating FRITZ and soulspace, Vivantes Hospital Am Urban and Vivantes Hospital Im Friedrichshain, Charité-Universitätsmedizin, Dieffenbachstraße 1, 10967, Berlin, Germany.
Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Eur Arch Psychiatry Clin Neurosci. 2022 Oct;272(7):1-14. doi: 10.1007/s00406-022-01379-8. Epub 2022 Feb 9.
The objective of the study was to investigate the development of clinical outcomes of young people with early psychosis in a specialized inpatient treatment and assess the feasibility of such an intervention in an inpatient setting. The study was a prospective cohort study of patients with early psychosis treated at the specialized inpatient treatment "Fühinterventions-und Therapiezentrum, FRITZ" (early intervention and therapy center) in Berlin, Germany. The primary outcomes were attitudes towards psychiatric medication and patient satisfaction with treatment after 6 weeks. Secondary outcomes were clinical symptoms, functioning, remission, recovery, all-cause treatment discontinuation, and rehospitalisation at 6 and 12 months after inpatient treatment. We recruited 95 inpatients with early psychosis. Attitudes towards psychiatric medication (Δ = 3.00, d = 0.55; Δ = 2.15, d = 0.35; Δ = 3.03, d = 0.52) and patient satisfaction (Δ = 0.21, d = 0.40; Δ = 0.32, d = 0.43; Δ = 0.13, d = 0.17) changed with medium effect sizes at six weeks up to a 6- and 12-month follow-up. Clinical outcomes changed significantly with medium-to-large-effect sizes over 12 months CGI = 1.64, d = -1.12; PANSS total = 20.10, d = -0.76; GAF = 19.58, d = 1.25). The all-cause treatment discontinuation rate was 13.69% (n = 13) at a 6-month and 35.79% (n = 34) at a 12-month follow-up. The rehospitalization rate was 30.53% (n = 29) at a 6-month and 43.16% (n = 41) at a 12-month follow-up. Patients with specialized inpatient treatment for early psychosis showed improvements in attitude towards psychiatric medication, patient satisfaction, symptoms, and functioning for up to 12 months.Trial registration: DRKS00024351, 2021/02/11 retrospectively registered.
本研究旨在探讨专门住院治疗中青年首发精神病患者的临床结局发展,并评估这种干预措施在住院环境中的可行性。该研究是一项对德国柏林专门住院治疗“Fühinterventions-und Therapiezentrum,FRITZ”(早期干预和治疗中心)治疗的早期精神病患者进行的前瞻性队列研究。主要结局是治疗 6 周后患者对精神药物的态度和对治疗的满意度。次要结局为临床症状、功能、缓解、康复、全因治疗中断以及住院治疗后 6 个月和 12 个月时的再住院率。我们招募了 95 名首发精神病患者。治疗 6 周后,患者对精神药物的态度(Δ=3.00,d=0.55;Δ=2.15,d=0.35;Δ=3.03,d=0.52)和对治疗的满意度(Δ=0.21,d=0.40;Δ=0.32,d=0.43;Δ=0.13,d=0.17)发生了具有中等效应大小的变化,直至 6 个月和 12 个月的随访。在 12 个月内,临床结局发生了显著变化,具有中到大效应大小CGI=1.64,d=-1.12;PANSS 总分=20.10,d=-0.76;GAF=19.58,d=1.25)。6 个月时的全因治疗中断率为 13.69%(n=13),12 个月时为 35.79%(n=13)。6 个月时的再住院率为 30.53%(n=29),12 个月时为 43.16%(n=41)。接受早期精神病专门住院治疗的患者在 12 个月内对精神药物的态度、对治疗的满意度、症状和功能均有改善。
DRKS00024351,2021 年 2 月 11 日回顾性注册。